Common Stock, par value $0.007 per share
- Symbol
- BIAF
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On October 13, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the Company’s sputum-based tests in development to characterize lung inflammation and detect multiple protein biomarkers of lung inflamm…
Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Current securities
Registered securities in this filing
bioAffinity Technologies, Inc. · 8-K · Filed 2026-10-13
Warrants to purchase Common Stock
- Symbol
- BIAFW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
October 13, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing
that it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the Company’s sputum-based
tests in development to characterize lung inflammation and detect multiple protein biomarkers of lung inflammation, including biologic
drug targets of therapeutics used to treat asthma and chronic obstructive pulmonary disease (COPD). These sputum-based tests are investigational,
have not been validated, are not cleared or approved by the U.S. Food and Drug Administration, and are not currently available for clinical
or diagnostic use..
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 News Release bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets Company advances research and development in diagnostic tests for major lung diseases building on CyPath® Lung + AI foundation Global asthma therapeutics market projected to reach $47.6 billion by 2034 SAN ANTONIO, Texas - October 13, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced it will present new data at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the Company’s sputum-based tests in development to characterize lung inflammation and detect multiple protein biomarkers of lung inflammation, including biologic drug targets of therapeutics used to treat asthma and chronic obstructive pulmonary disease (COPD). By providing a more complete picture of a…
Open exhibit ↗